

1 **Which came first, obstructive sleep apnea or hypertension?**

2 **A retrospective study of electronic records over 10 years, with**

3 **separation by sex**

4
5 Eunjoo An, PhD,¹ Michael R. Irwin, MD,^{2,4} Lynn V. Doering, PhD,¹ Mary-Lynn Brecht, PhD,¹ Karol E.
6 Watson, MD,³ Ravi S. Aysola, MD,⁵ Andrea P. Aguila, BA,¹ Ronald M. Harper, PhD,⁶ Paul M. Macey,
7 PhD^{1,6*}

8
9 UCLA School of Nursing¹; UCLA Jane and Terry Semel Institute for Neuroscience and Human
10 Behavior², Departments of Medicine-Division Cardiology³, Psychiatry⁴, Pulmonology⁵, and Brain
11 Research Institute⁶; University of California at Los Angeles, Los Angeles, California 90095

12
13 * Correspondence to:

14 Paul M. Macey
15 UCLA School of Nursing
16 700 Tiverton Ave
17 Los Angeles, CA 90095-1702
18 USA
19 Phone/voicemail: +1-424-234-3244
20 Email: pmacey@ucla.edu
21

22 **Funding**

23 This work was supported by NIH NR017435 (PMM) and NR017350 (EA), and National Center for
24 Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881.

25 **Competing interests**

26 The authors have no competing interests.

27 **Data sharing**

28 Data are available from a Harvard Dataverse repository¹.

29 **Word count**

30 3161 including references and legends.

31 **Abstract**

32 **Objectives:** Obstructive sleep apnea (OSA) is a risk factor for hypertension (HTN), but the clinical
33 progression of the sleep disorder to the high blood pressure condition is unclear. There are also sex
34 differences in prevalence, screening and symptoms of OSA. The objective was to estimate the time from
35 OSA to HTN diagnoses, with sex-specific quantification.

36 **Design:** Retrospective analysis of electronic health records (EHR) over a 10-year period (2006 to 2015
37 inclusive).

38 **Setting:** UCLA Health System in Los Angeles, California, USA.

39 **Participants:** 4848 patients: female N=2086, mean [age±std] = 52.8±13.2 years; male N=2762,
40 age=53.8±13.5 years. These patients were selected from 1.6 million patients with diagnoses in the EHR
41 who met the criteria of: diagnoses of OSA and HTN; in long-term care defined by ambulatory visits at
42 least one year prior and one year subsequent to the first OSA diagnosis; no diagnosis of OSA or HTN at
43 intake; and a sleep study performed at UCLA.

44 **Primary and secondary outcome measures:** The primary outcome measure in each patient was time
45 from the first diagnosis of OSA to the first diagnosis of HTN (in days). Since HTN and OSA are
46 progressive disorders, a secondary measure was relationship between OSA-to-HTN time and age.

47 **Results:** The mean, std and 95% confidence intervals of the time from OSA to HTN diagnoses were: all -
48 732 ± 1094.9 [-764.6, -701.8] days; female -815.9 ± 1127.3 [-867.3, -764.2] days; and male $-668.6 \pm$
49 1065.6 [-708.1, -626.8] days. Age was negatively related to time from OSA to HTN diagnosis in both
50 sexes.

51 **Conclusions:** HTN was on average diagnosed years prior to OSA, with a longer separation in females.
52 Our findings suggest under-screening of OSA, more so in females than males. Undiagnosed OSA may
53 delay treatment for the sleep disorder and perhaps affect the development and progression of HTN.

54 **Brief Summary**

- 55 • OSA is a risk factor for HTN so, in people with both conditions, the sleep disorder should
56 typically precede the high blood pressure. However, the clinical sequence of these two conditions
57 is unclear.
- 58 • For patients in long-term care in the UCLA health system, the diagnosis of OSA usually precedes
59 by years the diagnosis of HTN in patients with both conditions. The later diagnosis of OSA
60 versus HTN may reflect a lack of OSA screening for years after sleep disorder onset.

61

62 **Strengths and limitations of this study**

- 63 • Approximately 5000 is a large enough sample to provide reliable effect size and confidence
64 interval calculations.
- 65 • Inclusion criteria ensure observations are from patients likely to be in regular contact with the
66 UCLA health system, and hence to be in a position to be regularly screened for HTN and OSA.
- 67 • Separation by sex highlights the presence of clinical differences in patients with HTN and OSA,
68 although the nature of the differences (for example under-screening, or different progression in
69 females and males) cannot be inferred.
- 70 • Limited generalizability due to data in a single health system and to the specific 10-year time
71 period, the latter encompassing a change in diagnostic criteria for OSA.
- 72 • No data on diagnoses in other clinical settings or prior to 2006, meaning 1) many patients with
73 HTN and OSA were likely excluded because the diagnoses were not recorded at UCLA and 2) of
74 the included patients some may have had prior diagnoses thus affecting interpretation of the time
75 from OSA to HTN measure.

76 Introduction

77 Obstructive sleep apnea (OSA), a breathing disorder that effects around 30 million people nationally, is a
78 primary risk factor for hypertension (HTN)². When comorbid with OSA, HTN is often treatment-
79 resistant³. An accepted model is that OSA pathophysiology leads to HTN⁴, implying that treating OSA
80 would help prevent or resolve HTN⁵. However, randomized trials of treating OSA with continuous
81 positive airway pressure (CPAP) show modest effects on HTN⁵, confirming links between the two
82 conditions are not simplistic. Factors such as the association between rapid-eye movement (REM) OSA
83 and typical time time-of-night CPAP usage may explain the CPAP findings⁶, but further data are needed
84 to understand OSA-HTN relationships. Other relevant information is whether on average a diagnosis of
85 OSA precedes a diagnosis of HTN. Despite the accepted pathophysiologic model, there is little clinical
86 evidence on the question of whether OSA or HTN appear first in the clinical record. Even though there
87 are reasons other than disease progression that could influence the timing of diagnoses (differences in
88 HTN and OSA screening, multi-factorial nature of HTN), establishing the health record occurrence of
89 HTN relative to OSA would contribute to our understanding of clinical and maybe mechanistic
90 relationships between the conditions.

91 Assuming OSA is a precursor to HTN, we initially hypothesized that in patients with both conditions
92 a diagnosis of OSA precedes a diagnosis of HTN. This hypothesis also assumes equivalent screening for
93 both HTN and OSA, which, while unlikely to be true, nevertheless provides a starting point. Both HTN
94 and OSA are progressive so clinical diagnoses usually occur months to years after condition onsets. Since
95 screening for OSA is presumably less frequent than for HTN, the delay between onset and diagnosis
96 likely differs between the two conditions, with OSA most likely having a longer delay than HTN⁵.
97 Hence, a finding that OSA precedes HTN clinically would strongly support the model of OSA preceding
98 HTN; alternatively, if HTN precede OSA diagnoses, we could not rule out a longer delay to OSA
99 screening. In either case, quantifying the time between diagnoses would be useful.

100 Our objective was to test the hypothesis that OSA precedes HTN using electronic health records
101 (EHR) within the University of California, Los Angeles (UCLA) Health System. We assessed the time
102 between OSA and HTN diagnoses in patients with both conditions. We also aimed to describe timing of
103 diagnoses with respect to age and gender, since both factors influence prevalence and severity of both
104 conditions^{7,8}.

105 Methods

106 We evaluated EHR over a 10-year period beginning January 2006; the procedures were approved by the
107 UCLA Institutional Review Board. The patient records containing diagnoses of HTN or OSA were
108 retrieved. OSA was based on the following diagnostic codes: ICD-9 327.2, 327.20, 327.21, 327.2, 327.24
109 and 780.57; ICD-10 G47.30 and G47.33. HTN was based on: ICD-9 401.0, 401.1 and 401.9; ICD-10 I10.
110 During the timeframe, the American Academy of Sleep Medicine scoring rules for respiratory events
111 were updated^{9,10}; the UCLA Sleep Disorders Center transitioned from the 1999 to 2012 rules in the year
112 following their release. Furthermore, UCLA transitioned from ICD-9 to ICD-10 In patients with both
113 conditions, the time from first diagnosis of OSA to first diagnosis of HTN was calculated. The month and

114 day of the first encounter date was converted to January 1 to remove personal identifiers (date of visit),
115 but otherwise times between diagnoses were accurate to within a day. The day of first OSA diagnosis was
116 set as 0 (relative starting point), and the time difference represented as days to first HTN diagnosis. Sleep
117 study parameters were not available in the EHR.

118 We calculated descriptive statistics of time from OSA to HTN, including the mean which we tested
119 for being non-zero with a 1 sample t-test. The relationship between age and time from OSA to HTN was
120 calculated using a linear regression. We repeated these analyses for females and males separately. The
121 location of diagnoses (outpatient vs inpatient) within the 10-year period affects possible OSA to HTN
122 times, so we viewed these times separately by year and by gender. Statistics were calculated with
123 MATLAB.

124 Results

125 Of the 1.6 million patient records evaluated ($n = 1,654,067$) with at least one diagnosis, approximately
126 2% (29,764) contained OSA diagnoses and 14% (192,771) contained HTN diagnoses. There were 16,974
127 (1%) patient records with both diagnoses of OSA and HTN, of which 36% (6124) had a sleep study
128 within the UCLA Health System (A sleep study is required to diagnose OSA). We defined long-term care
129 as patients with encounters at least a year before and after OSA diagnosis, who comprise 29% (4848) of
130 records the OSA/HTN patients. Data are available online ¹.

131 Table 1 shows characteristics of OSA and HTN diagnoses and patient demographics, separated by
132 gender. Hypertension was typically diagnosed earlier than OSA ($P < 0.05$; mean time difference = -732
133 days; median = -532 days). Females showed earlier HTN diagnosis than males ($P < 0.05$ female vs. male;
134 days delay: females mean = -815.9 days/median = -610, males mean = -668.6 days/median = -451). Age
135 was negatively related to time from OSA to HTN diagnosis in both sexes ($P < 0.05$). These findings are
136 illustrated in Figures 1 and 2.

137 We repeated these analyses for the 16,974 records of all patients with HTN and OSA diagnoses and
138 the 6124 with a sleep study, and the direction of effects did not change for either set.

139 Discussion

140 From 2006 to 2016 in the UCLA Health System, HTN was on average diagnosed years prior to OSA,
141 with a longer separation in females. The time between diagnoses could reflect differences in screening,
142 specifically that HTN is more frequently screened than OSA. Assuming the OSA-causes-HTN model is
143 correct, these findings would reflect a delay in OSA relative to HTN screening of several years. An
144 alternative possibility is that OSA is not a principal mechanism of HTN—the findings could reflect both
145 conditions co-occurring, or that HTN may precede the development of OSA due to other factors. The
146 present data cannot distinguish between these possibilities. Practically speaking, a combination of effects
147 is likely at play, since there is more than one cause of HTN, just as OSA is a heterogenous disorder.

148 Considering possible common factors, the co-occurrence of OSA and HTN may be associated with
149 structural and biological effects of obesity, which is highly prevalent in both conditions ^{4 11}. In OSA, the
150 extra layer of adipose tissue surrounding the neck may contribute to the narrowing of the upper airway,

151 and rigidity of the thoracic and abdomen walls due to the adipose tissue deposits surrounding tissues,
152 further compromising the air flow¹². In HTN, an increase in adipose tissue, especially surrounding the
153 abdomen wall, may contribute to progression of HTN due to excess amount of adipokines produced^{13 14}.
154 Adipokines play a key role in body homeostasis, including insulin regulation, lipid and glucose
155 metabolism, coagulation, and angiogenesis and vascular remodeling, which all affect blood pressure
156 regulation¹⁴.

157 The longer separation seen in females may be partially explained by more frequent screening in males
158 due to differences in clinical presentation between the genders. For instance, women typically report
159 fatigue, insomnia, and depression, symptoms not classically associated with OSA, whereas, men typically
160 report daytime sleepiness, the defining symptom of the sleep disorder¹⁵. Sex differences in OSA, such as
161 structural changes in the brain¹⁶ and menopause,¹⁷ mean that the OSA-HTN relationship may differ
162 between males and females. Pre-menopausal women and postmenopausal women on hormone
163 replacement therapy have shown significantly lower OSA prevalence, suggesting hormones may have a
164 protective role women¹⁸. Other major differences between the sexes are that men have a higher
165 prevalence of OSA than women by a factor of 2:1¹¹, which could influence the likelihood of screening
166 based on expectations that males are more likely to have the sleep condition.

167 While these findings are from one health system and may not generalize, our analysis could be
168 replicated with other EHR datasets. The analysis could also be replicated in future time periods, since
169 screening for OSA may improve with time. OSA is a relatively recently discovered disease, and
170 awareness has been an increasing over the past two decades¹¹. Similarly, screening for HTN, perhaps
171 with home testing, may also lead to earlier diagnosis relative to onset, so the patterns seen from 2006 to
172 2016 may well differ in the future. Additionally, the present data and the refractory nature of HTN in
173 CPAP-treated OSA leave open the possibility that the model of OSA as principal mechanism of high
174 blood pressure is complex and may warrant consideration of additional factors such as obesity and other
175 comorbid conditions, or even bi-directional influences¹⁹.

176 **References**

- 177 1. Macey P. Days between diagnosis of obstructive sleep apnea and hypertension. 2019 doi:
178 10.7910/DVN/ZY1LDT [published Online First: 2019-10-02]
- 179 2. Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults.
180 *Am J Epidemiol* 2013;177(9):1006-14. doi: 10.1093/aje/kws342 [published Online First:
181 2013/04/17]
- 182 3. Gonzaga C, Bertolami A, Bertolami M, et al. Obstructive sleep apnea, hypertension and cardiovascular
183 diseases. *J Hum Hypertens* 2015;29(12):705-12. doi: 10.1038/jhh.2015.15 [published Online
184 First: 2015/03/13]
- 185 4. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered
186 breathing and hypertension. *N Engl J Med* 2000;342(19):1378-84. doi: MJBA-421901 [pii]
187 10.1056/NEJM200005113421901 [published Online First: 2000/05/11]
- 188 5. Jonas DE, Amick HR, Feltner C, et al. Screening for Obstructive Sleep Apnea in Adults: Evidence
189 Report and Systematic Review for the US Preventive Services Task Force. *JAMA*
190 2017;317(4):415-33. doi: 10.1001/jama.2016.19635 [published Online First: 2017/01/25]
- 191 6. Mokhlesi B, Finn LA, Hagen EW, et al. Obstructive sleep apnea during REM sleep and hypertension.
192 results of the Wisconsin Sleep Cohort. *Am J Respir Crit Care Med* 2014;190(10):1158-67. doi:
193 10.1164/rccm.201406-1136OC [published Online First: 2014/10/09]
- 194 7. Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general
195 population: A systematic review. *Sleep Med Rev* 2017;34:70-81. doi: 10.1016/j.smrv.2016.07.002
196 [published Online First: 2016/08/29]
- 197 8. Fryar CD, Ostchega Y, Hales CM, et al. Hypertension Prevalence and Control Among Adults: United
198 States, 2015-2016. *NCHS Data Brief* 2017(289):1-8. [published Online First: 2017/11/21]
- 199 9. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement
200 techniques in clinical research. The Report of an American Academy of Sleep Medicine Task
201 Force. *Sleep* 1999;22(5):667-89.
- 202 10. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the
203 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep
204 Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med*
205 2012;8(5):597-619. doi: 10.5664/jcsm.2172 [published Online First: 2012/10/16]
- 206 11. Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population—a review
207 on the epidemiology of sleep apnea. *J Thorac Dis* 2015;7(8):1311-22. doi: 10.3978/j.issn.2072-
208 1439.2015.06.11
- 209 12. Suratt PM, Wilhoit SC, Hsiao HS, et al. Compliance of chest wall in obese subjects. *J Appl Physiol*
210 *Respir Environ Exerc Physiol* 1984;57(2):403-7. doi: 10.1152/jappl.1984.57.2.403 [published
211 Online First: 1984/08/01]
- 212 13. Ostchega Y, Hughes JP, Terry A, et al. Abdominal obesity, body mass index, and hypertension in US
213 adults: NHANES 2007-2010. *Am J Hypertens* 2012;25(12):1271-8. doi: 10.1038/ajh.2012.120
214 [published Online First: 2012/08/17]

- 215 14. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. *Diabetes Metab* 2004;30(1):13-9.
216 [published Online First: 2004/03/19]
- 217 15. Eliasson AH, Kashani MD, Howard RS, et al. Fatigued on Venus, sleepy on Mars-gender and racial
218 differences in symptoms of sleep apnea. *Sleep Breath* 2015;19(1):99-107. doi: 10.1007/s11325-
219 014-0968-y [published Online First: 2014/03/19]
- 220 16. Macey PM, Kumar R, Yan-Go FL, et al. Sex differences in white matter alterations accompanying
221 obstructive sleep apnea. *Sleep* 2012;35(12):1603-13. doi: 10.5665/sleep.2228 [published Online
222 First: 2012/12/04]
- 223 17. Mirer AG, Young T, Palta M, et al. Sleep-disordered breathing and the menopausal transition among
224 participants in the Sleep in Midlife Women Study. *Menopause* 2017;24(2):157-62. doi:
225 10.1097/GME.0000000000000744 [published Online First: 2016/10/26]
- 226 18. Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects
227 of gender. *Am J Respir Crit Care Med* 2001;163(3 Pt 1):608-13.
- 228 19. Torres G, Sanchez-de-la-Torre M, Barbe F. Relationship Between OSA and Hypertension. *Chest*
229 2015;148(3):824-32. doi: 10.1378/chest.15-0136 [published Online First: 2015/04/17]
- 230

231 **Table**

232 **Table 1—Patient characteristics separated by gender.**

233 **A.** Days from first OSA to first HTN diagnosis ($t_{O \rightarrow H}$); mean and 95% confidence intervals [CI], median,
 234 and regression model by age. **B.** Demographics. Approximate age at time of OSA diagnosis. BMI was the
 235 closest recorded value to the date of OSA diagnosis; N indicates subset of patients with BMI values. Race
 236 and ethnicity were as recorded in EHR.

A		Time from OSA to HTN	All (n=4848)	Females (n=2086)	Males (n=2762)
		($t_{O \rightarrow H}$) days			
		mean \pm std	-732 \pm 1094.9	-815.9 \pm 1127.3	-668.6 \pm 1065.6
		[95% CI]	[-764.6, -701.8]	[-867.3, -764.2]	[-708.1, -626.8]
		median	-532	-610	-451
		model by age (all $p < 0.05$)	-16.9 \times Age + 299.3	-18.3 \times Age + 301.2	-15.9 \times Age + 302.5
		$t_{O \rightarrow H} = \beta_1 \times \text{Age} + \beta_0$			
Distribution					
		HTN before OSA	71.7%	75.2%	69.1%
		HTN with OSA (within 40 days)	7.0%	5.9%	7.9%
		HTN after OSA	21.2%	18.9%	23.0%
Encounters					
		N total	299 \pm 247	345 \pm 256	263 \pm 234
		N before OSA	81 \pm 92	98.4 \pm 99	67 \pm 83
		N after OSA	218 \pm 211	248 \pm 223	195 \pm 199
B		Demographics	All (n=4848)	Females (n=2086)	Males (n=2762)
		Age at OSA diagnosis mean \pm std (years)	53.3 \pm 13.4	52.8 \pm 13.2	53.8 \pm 13.5
		BMI m ² /kg N measurements	30.9 \pm 7.5 N = 3149/4848	32.6 \pm 8.4 N = 1411/2086	29.6 \pm 6.3 N = 1738/2762
Race		Native American /Pacific Islander	<1%	<1%	<1%
		Asian	9.8%	9.5%	10.1%
		Black or African American	12.5%	18.7%	7.8%
		White or Caucasian	66.7%	61.5%	70.6%
		Not specified/multiple	10.3%	9.5%	10.9%
Ethnicity		Hispanic/Latino	12.9%	16.3%	10.3%
		Not Hispanic Latino	84.9%	82.6%	86.7%
		Not specified	2.2%	1.2%	3.0%



238 **Figure Legends**

239 **Figure 1. Time from OSA to HTN: Distribution and time by age, separated by sex**

240 **A.** Distribution of time from OSA to HTN diagnoses, for combined (“ALL”) and female and male
241 patients; ± 10 year and ± 9 month ranges are shown. **B.** Scatterplots of time from OSA to HTN diagnoses
242 with respect to age at OSA diagnosis, for combined (“ALL”) and female and male patients.

243 **Figure 2. Distribution by year of OSA diagnosis in patients with OSA and HTN**

244 Distribution by year of time from OSA to HTN diagnoses, with box plots by year of OSA diagnosis (box
245 is between 25th and 75th percentiles, red line is median, whisker lines are ranges with outliers defined as
246 more than one interquartile range from box marked as red “+”). Grey areas indicate no data are available
247 for diagnoses prior to 2006 or after 2015 (so a delay from before 2006 or after 2015 could not be
248 observed).

A. Distribution of OSA to HTN (Days)**B. OSA to HTN by Age**

Distribution by year

